Terms of Participation

1. Organiser

The FluxSense Award is organised by:

Healthy Pleasures
Owner: Catharina Banach
Duisburger Straße 9
40477 Düsseldorf, Germany

Email: info@fluxsense-award.com

For information about the processing of personal data and data-protection enquiries, please see our Privacy Policy.

2. Purpose of the award

The FluxSense Award is an international award for innovative solutions in Digital Health, Health Technology, wearables and related areas of health innovation.

The award recognises solutions, companies and innovations that combine technology, scientific or evidence-based approaches, usability and a demonstrable benefit for people.

The FluxSense Award aims to make outstanding innovations visible and strengthen their international recognition, credibility and market position. The award is independent and organised by Healthy Pleasures.

3. Categories

The FluxSense Award 2027 comprises the following ten categories:

1. Best Consumer Health App
2. Best Preventive Health Technology
3. Best Health Tech Start-Up of the Year
4. Best Longevity Innovation
5. Best Wearable
6. Best Patient Care & Experience Solution
7. Best Women’s Health Solution
8. Best Mental Health Innovation
9. Best Connected Medical Device
10. Most Promising Vision

“Most Promising Vision” is intended for early concepts that are not yet fully product-ready. Assessment focuses in particular on the team, understanding and validation of the problem, vision and differentiation, feasibility based on a 12–18-month roadmap, and expected health impact.

The organiser reserves the right to adapt, combine, expand or discontinue categories for individual award cycles.

4. Eligibility

The FluxSense Award is international. Companies, start-ups, organisations and other providers of solutions in Health Tech, Digital Health, wearables and related fields of innovation may generally participate if their solution can be assigned to an advertised category.

Participation is possible regardless of the applicant’s place of establishment, provided the application meets the requirements of the chosen category.

The organiser may reject applications where the submitted solution clearly lacks a sufficient connection to the chosen category.

5. Award cycle and timeline

The award cycle generally consists of application, preliminary selection, jury evaluation, selection of finalists and the award.

The confirmed timeline for the 2027 award cycle is:

• Applications open: 1 January 2027
• Early Bird deadline: 31 January 2027
• Applications close: 1 March 2027
• Formal eligibility check: 2–10 March 2027
• Jury evaluation: 10 March–10 April 2027
• Final review of results: 10–20 April 2027
• Winners announced: 22 April 2027

The organiser may change deadlines for organisational reasons.

6. Application

Applications will be submitted using the application form provided on the website. Required information listed in the form must be complete and truthful.

The applicant’s self-assessment may include information about the company, the submitted solution, its innovation, application, benefits, market status and relevant supporting evidence.

Final required information, supporting documents, accepted file formats and size limits will be specified before applications open.

Applicants may voluntarily submit additional evidence, including studies, scientific publications or other material supporting a solution’s effectiveness, safety, usability or impact.

The current entry information page does not accept, save or upload applications and does not create a participation agreement.

7. Health and patient data

Applicants must not include personal health data, patient data or other special categories of personal data in an application unless this has been expressly agreed with the patients concerned.

In particular, no information may be submitted that would allow individual patients to be identified.

Studies or scientific evidence may be submitted provided they do not involve an unlawful disclosure of personal data. Applicants are responsible for checking documents before submission and anonymising or redacting them where necessary.

8. Accuracy and rights to submitted information

By submitting an application, the applicant confirms that the information is correct and complete to the best of their knowledge.

The applicant also warrants that they are entitled to submit the content and materials for participation in the award. This applies in particular to:

• Texts.
• Images.
• Graphics.
• Videos.
• Logos.
• Studies.
• Presentations.
• Other documents.

The applicant must ensure that the submission does not infringe the rights of third parties.

9. Intellectual property and trade secrets

Participation in the FluxSense Award does not transfer ownership, copyright, patent, trademark or other intellectual-property rights to the organiser.

In particular, participation does not transfer rights to the underlying technology, product, software, business model or other intellectual property.

Applicants should not submit information they treat as a trade secret if disclosure could adversely affect their business or legal position.

The organiser cannot guarantee absolute confidentiality towards third parties where disclosure is legally required or results from technical or organisational circumstances outside the organiser’s control.

10. Confidentiality of applications

Applications will be treated confidentially and used exclusively to conduct and evaluate the FluxSense Award.

The jury and other persons involved in evaluation receive only the information necessary to assess the application and submitted by the applicant.

Submitting an application does not constitute consent to publication of its full content. The organiser will not publish confidential business documents or information in an application that is not intended for public disclosure.

Information underlying an application and statements by jury members may be used to report award results to the press. This does not include publication of confidential application information.

11. Evaluation procedure

A preliminary selection takes place after the application deadline. Selected applications are then assessed by an independent jury.

The jury assesses applications in particular with regard to:

• Degree of innovation.
• Technological quality.
• Scientific or evidence-based foundations.
• Usability.
• Practical benefit.
• Impact.
• Differentiation.
• Potential for sustainable improvements in health or healthcare.

The organiser may adapt evaluation criteria for individual categories where appropriate to the different characteristics of the solutions.

12. Independent jury and conflicts of interest

The jury is assembled independently. Jury members should disclose possible conflicts of interest to the organiser.

A jury member should not evaluate an application if a personal, commercial or other conflict of interest exists.

Jury members will be published on the FluxSense Award website.

Sponsorship does not confer influence over evaluation, nomination or awards. Representatives of a Category Partner may not evaluate the category supported by their company. Sponsors do not receive application or contact data for their own use.

13. Jury decisions

The jury’s decision is generally binding. There is no entitlement to any particular assessment, ranking, nomination or award.

Legal challenges to the jury’s decision are excluded to the extent permitted by law.

The organiser is not obliged to disclose individual jury decisions or evaluation details.

14. Finalists and winners

Finalists are selected on the basis of the jury evaluation. The winners in each category are selected from the finalists.

Applying in several categories is generally possible.

Winners will be notified after the evaluation procedure using the contact details provided in their application.

15. Publication of nominees, finalists and winners

The names of nominated companies may be published on the FluxSense Award website and through the organiser’s other communication channels.

These may include:

• The website.
• Social media.
• Newsletters.
• Press releases.
• Editorial coverage.
• Marketing and communication materials.

This does not include publication of confidential application content.

16. Press and media coverage

The organiser may report on the FluxSense Award and its results.

Press and public-relations activities may use the names of nominated companies, finalists and winners, and general information about their recognised solutions.

Individual statements or assessments by jury members may also be published in edited or shortened excerpts.

This does not include publication of confidential application information.

17. Award benefits

Winners of the FluxSense Award receive in particular:

• The FluxSense Award Badge as an award emblem or digital award asset.
• The opportunity to use the award in their corporate communications.
• International visibility through FluxSense communication channels.
• The opportunity to use the award for marketing, PR and social media.
• Greater visibility among healthcare leaders, experts, investors, media representatives and strategic partners.
• The opportunity to use the award to differentiate their solution in the market.
• The opportunity to refer to the award in discussions with healthcare partners and institutions.
• Additional external recognition of their Health Tech solution.
• One exclusive consultation opportunity with a Health Tech strategy expert, by individual arrangement.

The specific benefits are those published on the website at the time of the award.

Benefits do not guarantee specific media coverage, investments, business opportunities, customer contacts, increased revenue or other commercial outcomes.

18. Award badge and use of the brand

Winners may use the FluxSense Award Badge in connection with their recognised solution and corporate communications.

Use must be truthful and must not suggest that the organiser guarantees continuing certification, medical approval, clinical effectiveness or regulatory approval of the recognised solution.

The distinction is an award, not a medical, regulatory or scientific certification.

The organiser may revoke permission to use the badge in cases of misuse or misleading use.

19. Entry fees

An entry fee is charged for participation in the FluxSense Award:

• Early Bird: €310 — until 31 January 2027
• Regular Entry: €399

All entry fees are exclusive of VAT. Payment conditions will be published before applications open. No fee is currently collected through this website.

The fee applies to one submission in one category and covers only the processing and assessment of that submission. Payment does not create an entitlement to nomination, selection as a finalist or an award.

The entry fee is charged as part of the application process regardless of the evaluation outcome.

If the award cannot take place due to circumstances beyond the organiser’s control, entry fees will be refunded.

20. Multiple submissions

An applicant may generally submit several solutions, or the same solution in several categories, provided each meets the relevant requirements.

A separate entry fee may apply to each submission. The final fee for submitting the same solution in an additional category will be published with the entry-fee schedule before applications open.

Submitting a different solution by the same provider in another category counts as a separate regular application.

21. Exclusion of applications

The organiser may exclude applications in particular where:

• The application contains clearly false or misleading information.
• The application does not fit the chosen category.
• Third-party rights are infringed.
• Unlawful personal data or patient data are submitted.
• The application violates applicable law.
• The entry fee remains unpaid despite an obligation to pay.
• The application is submitted after the deadline.
• The applicant attempts to influence or manipulate the evaluation procedure.

In the event of exclusion, there is generally no entitlement to a refund of the entry fee.

22. Changes and cancellation of the award

The organiser reserves the right, for good cause, to change or postpone the award cycle, discontinue individual categories or cancel the award entirely.

This applies in particular to technical, organisational, legal or economic circumstances that make proper conduct of the award impossible or unreasonable.

If the organiser cancels the award entirely, entry fees will be refunded. If dates change, the regular fee continues to apply.

23. Liability

The organiser is liable under statutory provisions for damage caused intentionally or through gross negligence.

For damage caused by slight negligence, the organiser is liable only for breaches of essential contractual obligations and only for foreseeable damage typical of the contract.

The organiser does not guarantee:

• The commercial success of participation.
• Specific media coverage.
• Investment or financing.
• Customer contacts.
• Partnerships.
• Market opportunities.
• Increased revenue.
• Any particular reach of award communications.

Jury members undertake to maintain the confidentiality and protection of the applicant information submitted for the award and are liable for fulfilling that obligation.

24. No medical or regulatory certification

The FluxSense Award does not constitute medical, scientific, regulatory or official certification.

An award does not mean that a solution is:

• Medically approved.
• Clinically effective.
• Compliant with regulatory requirements.
• Assessed by a health authority.
• Suitable for a particular medical treatment.

Responsibility for regulatory approvals, medical claims, scientific evidence and lawful marketing remains exclusively with the respective provider.

25. Data protection

Personal data in connection with the FluxSense Award are processed in accordance with the applicable data-protection provisions.

Further information is available in the FluxSense Award Privacy Policy.

By participating, applicants confirm that they have read the Privacy Policy.

26. Governing law

The law of the Federal Republic of Germany applies, excluding the United Nations Convention on Contracts for the International Sale of Goods, unless mandatory statutory provisions provide otherwise.

Consumers retain the protection of mandatory statutory provisions in the country where they habitually reside.

27. Jurisdiction

To the extent permitted by law, the organiser’s place of establishment is the place of jurisdiction for disputes with businesses.

Statutory rules on jurisdiction apply to consumers.

28. Final provisions

If an individual provision of these terms is or becomes wholly or partly invalid, the remaining provisions remain unaffected.

An invalid provision will be replaced by a legally permissible provision that comes closest to its economic purpose.

29. Contact

For questions about the FluxSense Award, please contact:

FluxSense Award / Healthy Pleasures
Owner: Catharina Banach
Email: info@fluxsense-award.com

For data-protection enquiries, please use the contact information in our Privacy Policy.